Navigation Links
VioQuest Pharmaceuticals Completes Enrollment of Phase I Trial of Lenocta(TM)
Date:10/10/2007

(NDA) to the U. S. Food and Drug Administration (FDA) in 2007 for Lenocta(TM) for the treatment of leishmaniasis.

Forward-Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties that could cause VioQuest's actual results and experiences to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These forward-looking statements concern the timing, progress and results of the clinical development, regulatory processes, and potential clinical trial initiations of Lenocta. These statements are often, but not always, made through the use of words or phrases such as anticipates, expects, plans, believes, intends, and similar words or phrases. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. These statements are subject to various risks and uncertainties and include the possibility that the results of clinical trials will not support VioQuest's claims, the possibility that VioQuest's development efforts relating to its product candidates, including Lenocta(TM), will not be successful, the inability to obtain regulatory approval of VioQuest's product candidates, VioQuest's reliance on third-party researchers to develop its product candidates, its lack of experience in developing and commercializing pharmaceutical products, and the possibility that its licenses to develop and commercialize its product candidates may be terminated. Additional risks are described in VioQuest's Annual Report on Form 10-KSB for the year ended December 31, 2006. VioQuest assumes no obligation and does not intend to update these forward-looking statements, except as required by law.

Contact information:

Daniel Greenleaf

President and CEO

908-766-4400 ext. 115


SOURCE VioQuest Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. VioQuest Pharmaceuticals Announces Data Presentation for Its Akt Inhibitor VQD-002, at American Association for Cancer Research Annual Meeting
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2014)...  Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR ) ... (FDA) accepted the company,s Investigational New Drug (IND) application ... efficacy of AVP-786, Avanir,s next generation compound. The company ... adjunctive treatment of major depressive disorder (MDD) during the ... endorsement of this Phase II study by the division ...
(Date:7/21/2014)... 21, 2014 Sorrento Therapeutics, Inc. (NASDAQ: ... developing new treatments for cancer and its associated pain, ... the preclinical development of a small molecule inhibitor targeting ... The Myc protein has also been recognized as an ... is involved as a dominant factor in most human ...
(Date:7/21/2014)... LA JOLLA, Calif. , July 21, 2014 ... RGLS ), a biopharmaceutical company leading the discovery ... today that the U.S. Food & Drug Administration ... a single stranded, chemically modified oligonucleotide that binds ... as a therapeutic for the treatment of Alport ...
Breaking Medicine Technology:Avanir Pharmaceuticals Announces FDA Acceptance of IND for AVP-786 for the Adjunctive Treatment of Major Depressive Disorder 2Avanir Pharmaceuticals Announces FDA Acceptance of IND for AVP-786 for the Adjunctive Treatment of Major Depressive Disorder 3Avanir Pharmaceuticals Announces FDA Acceptance of IND for AVP-786 for the Adjunctive Treatment of Major Depressive Disorder 4Avanir Pharmaceuticals Announces FDA Acceptance of IND for AVP-786 for the Adjunctive Treatment of Major Depressive Disorder 5Sorrento Awarded Grant from the National Institutes of Health for the Development of a Small Molecule Myc Inhibitor 2Sorrento Awarded Grant from the National Institutes of Health for the Development of a Small Molecule Myc Inhibitor 3Sorrento Awarded Grant from the National Institutes of Health for the Development of a Small Molecule Myc Inhibitor 4Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 2Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 3Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 4Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 5
... Inc. (OTCPK: SNDY) is pleased to announce that the Company ... in the amount of $90,005. The revenue for the three ... fifty Hospitals, Clinics, Healthcare Centers, Medical Centers and Surgery Centers ... growth in 2011 through new product development, new product sales ...
... Ireland, Jan. 27, 2011 Tibotec Pharmaceuticals today ... to generic manufacturers including Hetero Drugs Limited, Matrix ... Aspen Pharmacare of South Africa to manufacture, market ... rilpivirine hydrochloride (TMC278), pending ...
Cached Medicine Technology:Solos Endoscopy, Inc. Reports $90,005 in Sales Revenue for Fourth Quarter 2010 2Tibotec Signs Multiple Agreements With Generic Manufacturers to Provide Access to New HIV Treatment 2Tibotec Signs Multiple Agreements With Generic Manufacturers to Provide Access to New HIV Treatment 3Tibotec Signs Multiple Agreements With Generic Manufacturers to Provide Access to New HIV Treatment 4
(Date:7/22/2014)... Getting breast implants is a choice, but deciding ... to medical necessity. Either way, women should know what to ... says Robert Kraft, MD, Plastic Surgeon with Advanced Dermatology, ... performed each year in the United States, according to the ... procedures stem from three main problems: the breast implant has ...
(Date:7/22/2014)... A new and technologically unique procedure called ... that are surprising even the most skeptical plastic surgeons. ... radio frequency, ThermiTight has been dubbed “InjectableRF” because it ... to “inject” heat to the tissues which cause sagging ... solution for skin laxity produces results in weeks, with ...
(Date:7/21/2014)... (PRWEB) July 22, 2014 On Monday, September ... Charity Golf Outing honoring Mike McGuriman-Motorola Solutions at The Knoll ... outing begins with registration and lunch at 11 a.m. ... and prizes. Price increases to $250 after September 7th. ... for $100 per person. The dinner will include a ...
(Date:7/21/2014)... MINNEAPOLIS, Minnesota (PRWEB) July 21, 2014 ... on providing service, support, education, and add-ons for ... Microsoft Dynamics Inner Circle, an elite group of ... the globe with sales achievements that rank them ... global network of partners. Members of the Microsoft ...
(Date:7/21/2014)... It,s human nature to hate losing. , Unfortunately, ... potentially abandoning a solid strategy and thus increasing your ... one conclusion of a Brigham Young University study published ... The finding is based on an analysis of two ... researchers focused on whether coaches adjusted their personnel following ...
Breaking Medicine News(10 mins):Health News:Is Breast Implant Removal Right for You? Plastic Surgeon Dr. Robert Kraft With Advanced Dermatology, PC Explains Breast Implant Removal and Offers Tips On Procedure 2Health News:Is Breast Implant Removal Right for You? Plastic Surgeon Dr. Robert Kraft With Advanced Dermatology, PC Explains Breast Implant Removal and Offers Tips On Procedure 3Health News:New Minimally Invasive Procedure, ThermiTight, “Injects” Radio Frequency to Treat Skin Laxity 2Health News:7th Annual Push to Walk Golf Outing to Be Held September 22nd 2Health News:PowerObjects Joins the 2014 Microsoft Dynamics Inner Circle 2Health News:'Moral victories' might spare you from losing again 2
... , CHICAGO, Sept. 1 In ... which shows young athletes with repeated brain injuries are at ... Association (IATA) and the Chicago Institute of Neurosurgery and Neuroresearch ... and monitoring concussions. The complimentary card is an educational tool ...
... , , , FRANKLIN LAKES, N.J., Sept. 1 ... announced today that it would present at the following investor healthcare conferences in September: , ... September 9, 2009, ... Conference, September 14, 2009, ...
... than laparoscopic surgery, study finds , TUESDAY, Sept. 1 ... pelvic pain by disrupting nerve connections failed to improve ... researchers say. , The nerve-disruption procedure "did not alleviate ... irrespective of the presence or absence of mild endometriosis," ...
... , , WARSAW, Ind., Sept. 1 Zimmer ... be participating in the following investor conferences during the month of September: , ... Conference 2009 in Boston, Mass., on September 9, 2009, at 11:30 a.m. Eastern ... New York, N.Y., on September 14, 2009, at 8:35 a.m. Eastern Time; and ...
... "Saturday ... Dr. Lonnie Paulos now beginning its second year , ... Gulf Breeze, FL (Vocus) September 1, 2009 -- ... orthopaedic exams and assessments to high school and collegiate athletes on Saturday mornings. ...
... , KANSAS CITY, Mo., Sept. 1 ... with medical challenges often unique to members of the military. From ... some of the most pressing conditions confronting the health care system ... Release, go to: http://www.prnewswire.com/mnr/militaryhealth/39824/ , ...
Cached Medicine News:Health News:Illinois Athletic Trainers and Physicians Offer Handy Wallet Card to Tackle Concussions 'Head On' 2Health News:Two Treatments Equally Effective for Chronic Pelvic Pain 2Health News:Andrews Institute for Orthopaedics and Sports Medicine Now Providing Free Orthopaedic Exams and Assessments on Saturday Mornings to Student Athletes 2Health News:Andrews Institute for Orthopaedics and Sports Medicine Now Providing Free Orthopaedic Exams and Assessments on Saturday Mornings to Student Athletes 3Health News:Video: Physical and Mental Health of U.S. Warfighter Is Focus of Military Health Research Forum 2